OM
CYTO

Opaleye Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Opaleye Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4
Closed -$1.43M – 53
2016
Q2 		$1.43M Hold
4
– – 0.95% 39
2016
Q1 		$1.24M Sell
4
-1
-20% -$356K 0.77% 38
2015
Q4 		$1.83M Buy
5
+1
+25% +$288K 0.77% 42
2015
Q3 		$1.26M Hold
4
– – 0.62% 40
2015
Q2 		$1.73M Buy
+4
New +$1.66M 0.69% 35

Other funds holding CYTO

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Opaleye Management's CYTO Position: Q3 2016 in Review

Opaleye Management sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2016, closing a stake of 4 shares — an estimated $1.43M sold.

Opaleye Management first reported a position in CYTO in Q2 2015 and held it in 5 quarters. The position peaked at $1.83M in Q4 2015. 3 funds tracked by Wall St. Rank hold CYTO as of Q3 2016.

  • Opaleye Management reported no remaining Altamira Therapeutics Ltd position as of Q3 2016 after selling out during the quarter.
  • Opaleye Management sold 4 Altamira Therapeutics Ltd shares in Q3 2016, an estimated $1.43M.
  • Opaleye Management first reported a position in Altamira Therapeutics Ltd in Q2 2015 and held it in 5 quarters.
  • Opaleye Management's Altamira Therapeutics Ltd position peaked at $1.83M in Q4 2015.
  • 3 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2016.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.